These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 25481047)
1. Glatiramer acetate guards against rapid memory decline during relapsing-remitting experimental autoimmune encephalomyelitis. LoPresti P Neurochem Res; 2015 Mar; 40(3):473-9. PubMed ID: 25481047 [TBL] [Abstract][Full Text] [Related]
2. Restoration of axon conduction and motor deficits by therapeutic treatment with glatiramer acetate. Moore S; Khalaj AJ; Patel R; Yoon J; Ichwan D; Hayardeny L; Tiwari-Woodruff SK J Neurosci Res; 2014 Dec; 92(12):1621-36. PubMed ID: 24989965 [TBL] [Abstract][Full Text] [Related]
3. Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate. Aharoni R; Vainshtein A; Stock A; Eilam R; From R; Shinder V; Arnon R J Autoimmun; 2011 Nov; 37(3):228-41. PubMed ID: 21752599 [TBL] [Abstract][Full Text] [Related]
4. Cognitive impairment in an animal model of multiple sclerosis and its amelioration by glatiramer acetate. Aharoni R; Schottlender N; Bar-Lev DD; Eilam R; Sela M; Tsoory M; Arnon R Sci Rep; 2019 Mar; 9(1):4140. PubMed ID: 30858445 [TBL] [Abstract][Full Text] [Related]
5. Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies. Teitelbaum D; Aharoni R; Klinger E; Kreitman R; Raymond E; Malley A; Shofti R; Sela M; Arnon R Ann N Y Acad Sci; 2004 Dec; 1029():239-49. PubMed ID: 15681762 [TBL] [Abstract][Full Text] [Related]
6. Glatiramer acetate-specific antibody titres in patients with relapsing / remitting multiple sclerosis and in experimental autoimmune encephalomyelitis. Bomprezzi R; Schaefer R; Reese V; Misra A; Vollmer TL; Kala M Scand J Immunol; 2011 Sep; 74(3):219-226. PubMed ID: 21615449 [TBL] [Abstract][Full Text] [Related]
7. Glatiramer Acetate: from Bench to Bed and Back. Arnon R; Aharoni R Isr Med Assoc J; 2019 Mar; 21(3):151-157. PubMed ID: 30905097 [TBL] [Abstract][Full Text] [Related]
10. Axonal damage is reduced following glatiramer acetate treatment in C57/bl mice with chronic-induced experimental autoimmune encephalomyelitis. Gilgun-Sherki Y; Panet H; Holdengreber V; Mosberg-Galili R; Offen D Neurosci Res; 2003 Oct; 47(2):201-7. PubMed ID: 14512144 [TBL] [Abstract][Full Text] [Related]
11. Magnetic resonance imaging characterization of different experimental autoimmune encephalomyelitis models and the therapeutic effect of glatiramer acetate. Aharoni R; Sasson E; Blumenfeld-Katzir T; Eilam R; Sela M; Assaf Y; Arnon R Exp Neurol; 2013 Feb; 240():130-44. PubMed ID: 23153580 [TBL] [Abstract][Full Text] [Related]
12. Immunomodulation neuroprotection and remyelination - the fundamental therapeutic effects of glatiramer acetate: a critical review. Aharoni R J Autoimmun; 2014 Nov; 54():81-92. PubMed ID: 24934599 [TBL] [Abstract][Full Text] [Related]
13. Two decades of glatiramer acetate: From initial discovery to the current development of generics. Weinstock-Guttman B; Nair KV; Glajch JL; Ganguly TC; Kantor D J Neurol Sci; 2017 May; 376():255-259. PubMed ID: 28431621 [TBL] [Abstract][Full Text] [Related]
14. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy. Teitelbaum D; Brenner T; Abramsky O; Aharoni R; Sela M; Arnon R Mult Scler; 2003 Dec; 9(6):592-9. PubMed ID: 14664472 [TBL] [Abstract][Full Text] [Related]
15. Translocator Protein Ligand PIGA1138 Reduces Disease Symptoms and Severity in Experimental Autoimmune Encephalomyelitis Model of Primary Progressive Multiple Sclerosis. Tremolanti C; Cavallini C; Meyer L; Klein C; Da Pozzo E; Costa B; Germelli L; Taliani S; Patte-Mensah C; Mensah-Nyagan AG Mol Neurobiol; 2022 Mar; 59(3):1744-1765. PubMed ID: 35018577 [TBL] [Abstract][Full Text] [Related]